TARS News and Press, Tarsus Pharmaceuticals Inc. From 11/07/23

2023-11-07 07:02:08 ET Summary Demodex Blepharitis (DB), Meibomian Gland Dysfunction (MGD), Dry Eye, Rosacea, and Lyme Disease are common conditions that can be treated with XDEMVY™. XDEMVY™ (lotilaner ophthalmic solution 0.25%) is the first FDA-approved treatment fo...

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at ...

2023-10-19 11:54:12 ET Summary XDEMVY launch unlikely to succeed. Unlikely that Demodex-caused blepheritis is a common condition. Highly likely that Tarsus will never break even. Tarsus Pharmaceuticals (TARS) has made an impressive effort to transform a nasty do...

2023-10-09 11:43:20 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals: Worthy Of A Small Bet Tarsus Pharmaceuticals' President & CEO disposes 8,000 shares For further details see: Tarsus Pharmaceuticals CMO discloses sale of 1,604 company shares

2023-10-06 11:25:33 ET Summary Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come ...

2023-09-25 11:07:51 ET More on Tarsus Pharmaceuticals Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals Historical earnings data for Tarsus Pharmaceuticals Financial information for Tarsus Pharmaceuticals Tarsus granted FDA nod for lead asset ...

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief ...

2023-09-04 08:36:07 ET Summary Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just launched this product known by the brand name Xdemvy and is targeting optometrists and ophthalmologists....

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calli...

2023-08-11 11:19:08 ET Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q2 GAAP EPS of -$1.17. For further details see: Tarsus Pharmaceuticals GAAP EPS of -$1.17